Sunesis Pharmaceuticals, Inc. (Sunesis) is a biopharmaceutical company focused on the development and commercialization of oncology therapeutics for the treatment of solid and hematologic cancers. The Company is focuses primarily on the development of vosaroxin for the treatment of acute myeloid leukemia (AML). Vosaroxin is a anti-cancer quinolone derivative (AQD). AQDs have been shown to mediate anti-tumor activity by targeting mammalian topoisomerase II, an enzyme critical for cell replication. The Company owns worldwide development and commercialization rights to vosaroxin. The Company's VALOR trial is designed to evaluate the effect of vosaroxin in combination with cytarabine, chemotherapy in AML. The trial has an adaptive design and is based on data from the Company's Phase II clinical trial of vosaroxin in combination with cytarabine in relapsed or refractory AML.
395 Oyster Point Boulevard
SOUTH SAN FRANCISCO, CA, United States 94080
|President, Chief Executive Officer, Director||Daniel Swisher|
|Chief Financial Officer, Executive Vice President - Corporate Development and Finance||Eric Bjerkholt|
|Executive Vice President - Development, Chief Medical Officer||Adam Craig|
With TD Waterhouse, you have access to the industry's leading selection of independent research reports from providers such as TDSI, TD Securities, S&P, INK and Argus.
|Shares Out.||51.6M||Book Value||$0.23|
|Annual Dividend Rate||$0.00||Price/Sales (TTM)||49.6|
|Ex-Div Date||1/1/01||P/Cash Flow (TTM)||--|
|Pay Date||1/1/01||Operating Margin||-585.11%|
*GAAP = prior to non-GAAP analyst adjusted earnings.